Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune monotherapy plus/or probiotics in small cell lung cancer and gut microbiome evolution
ChiCTR2200067210Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Dalian Medical University
- Start
- Jan 2023
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of bacillus licheniformis, Medilac-S and bifidobacterium longum + lactobacillus acidophilus + enterococcus faecalis in small cell lung cancer (SCLC) (4 arms), sponsored by The Second Affiliated Hospital of Dalian Medical University. Primary endpoint: Overall survival. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
bacillus licheniformisMedilac-Sbifidobacterium longum + lactobacillus acidophilus + enterococcus faecalis
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2200067210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200067210.